Cytotoxic chemotherapy can control tumor burden in some patients with response rates of around 20% in old series. For the last 10 years, systemic therapy for MTC patients with large tumor burden and documented progression of the disease has involved the use of tyrosine kinase inhibitors targeting ...
The kinase structural domains of PTKs are responsible for transferring the phosphate group of ATP to the tyrosine residue of downstream signaling molecules. Regarding the structural similarity of TKIs and ATPs, TKIs can competitively bind to the kinase structural domains to prevent downstream pathway ac...
The tyrosine kinase inhibitor dasatinib potentiates CHOEP effects in malignant T-cell lines As all the above reported findings prompt to a role of the TCR signalling pathway activation in promoting pro-survival signals mainly mediated by SFKs in response to chemotherapy in TCL preclinical models, we...
Before any selective RET inhibitor becomes available, chemotherapy, multi-targeted TKIs, and clinical trials are common choices for RET-altered cancer patients. Multi-targeted TKIs including cabozantinib and vandetanib have been clinically used in RET-driven lung and thyroid cancers, but their insufficien...
Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. This aim of this study was to compare the efficacy of first-line tyrosine kinase inhibitor therapy followed, upon progression, by chemotherapy with ...
Masitinib, also a monoclonal antibody developed by AB science, is a receptor tyrosine kinase inhibitor. A phase two trial of masitinib showed an acceptable tolerance profile and was also found to decrease cognitive decline in patients with AD (Piette et al., 2011). A phase 3 clinical trial (...
Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. Lung Cancer. 2014;86(2):219-224.Zeng Z, Yan HH, Zhang XC, Zhong WZ, He YY, Guan JL, Niu FY, Xie Z, Huang YS, Xu CR, Dong S, Wu YL. Reduced chemotherapy sensitivity ...
Epidermal gro wth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) given concurrently with chemotherapy do not improve patient outcomes compared with chemotherapy alone in advancedstage non–small-cell lung cancer (NSCLC). One potential explanation for this lack of benefit is a negative interac...
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433–443. 61 Chu SH, Small D. Mechanisms of resistance to FLT3 inhibitors. Drug Resist Updat 2009; 12: 8–16. This work is licensed under a Creative Commons ...
TYROSINE KINASE INHIBITOR (TKI) THERAPY IN COMPANION ANIMALS: YEAR ONE 来自 掌桥科研 喜欢 0 阅读量: 1 作者: C London 摘要: Inhibitors of tyrosine kinases (TKIs) have become an integral part of human cancer therapy over the past 5-10 years. Drugs such as Gleevec, Sutent, Sorafenib, ...